Expertise in
10
conditions

Dr. Daniel R. Reed

Hematology
UVA Health University Medical Center
1215 Lee St, 
Charlottesville, VA 
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
UVA Health University Medical Center
1215 Lee St, 
Charlottesville, VA 

Overview

Daniel Reed is a Hematologist practicing medicine in Charlottesville, Virginia.

Dr. Reed is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Childhood Acute Myeloid Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 3 clinical trials. Dr. Reed is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in NC

Hospital Affiliations

Sentara Rmh Medical Center
University Of Virginia Medical Center
Augusta Health
Uva Health Culpeper Medical Center
Centra Health - Lynchburg Gen Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UVA Health University Medical Center
1215 Lee St, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Azacitidine, Pembrolizumab, Venetoclax
Study Phase: Phase 2
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cytarabine, Daunorubicin, Idarubicin, Pembrolizumab
Study Phase: Phase 2
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Procedure, Drug
Study Drug: Olaparib
Study Phase: Phase 2
View 2 Less Clinical Trials

24 Total Publications

The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
Journal: British journal of haematology
Published: July 02, 2026
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

UVA Health Emily Couric Clinical Cancer Center

1240 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-924-9333
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Portell is a Hematologist practicing medicine in Charlottesville, Virginia. Dr. Portell is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Portell is currently accepting new patients.

Expertise in
21
conditions
Dr. Benjamin W. Purow
Hematology | Oncology
Expertise in
21
conditions
Dr. Benjamin W. Purow
Hematology | Oncology
Referral may be required

UVA Health Neuro Oncology

1240 Lee St Fl 3, 
Charlottesville, VA 
 (1.2 miles away)
434-924-9333
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin Purow is a Hematologist and an Oncologist practicing medicine in Charlottesville, Virginia. Dr. Purow is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Purow is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

UVA Health University Medical Center

1215 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-924-3627
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Karen Ballen is a Hematologist practicing medicine in Charlottesville, Virginia. Dr. Ballen is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ballen is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel R. Reed

How do I make an appointment with Dr. Daniel R. Reed?

You can book an appointment with Dr. Daniel R. Reed by calling their office at 434-924-3627. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel R. Reed a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel R. Reed is classified as an Advanced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel R. Reed specialize in?

While Dr. Daniel R. Reed is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Childhood Acute Myeloid Leukemia, and Acute Myeloblastic Leukemia without Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Daniel R. Reed participate in research or clinical trials?

Yes. Dr. Daniel R. Reed has published 24 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Daniel R. Reed's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel R. Reed accept my insurance?

Dr. Daniel R. Reed accepts most major insurance plans, including Aetna and AmeriHealth. We recommend calling the office directly at 434-924-3627 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reed's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 30 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile